ETBX-011 clinical trials
Also written ETBX-011.
- studies test it
- 19
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses ETBX-011 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ETBX-011
- 17
Studies by the year they started
19 studies that test it; most in 2018 (10)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2017 | 8 |
| 2018 | 10 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 18 · Other 1
ImmunityBio, Inc. (16) · NantCell, Inc. (2) · National Cancer Institute (NCI) (1)
Often tested with
Tested in the same studies.
Nogapendekin alfa inbakicept (17) · GI-4000 (15) · ETBX-051 (13) · ETBX-061 (13) · GI-6301 (13) · Yeast-CEA vaccine (12) · ETBX-021 (7) · Mucin-1 (1)
Studies
Open first, then newest update. How each study uses ETBX-011 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 19
- QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEACompletedPhase 1/2NantCell, Inc.NCT01147965Written as Ad5 CEA VaccineHow we know
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169764Written as ETBX-011How we know
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03175666Written as ETBX-011How we know
- QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03563144Written as ETBX-011How we know
- QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerWithdrawnPhase 2ImmunityBio, Inc.NCT03574649Written as ETBX-011How we know
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169738Written as ETBX-011How we know
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03167177Written as ETBX-011How we know
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169777Written as ETBX-011How we know
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03197571Written as ETBX-011How we know
- QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03554109Written as ETBX-011How we know
- QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedPhase 1/2ImmunityBio, Inc.NCT03329248Written as ETBX-011How we know
- QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedPhase 1/2ImmunityBio, Inc.NCT03586869Written as ETBX-011How we know
- QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedPhase 1/2ImmunityBio, Inc.NCT03387085Written as ETBX-011How we know
- QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing CancerTerminatedPhase 1/2NantCell, Inc.NCT03127098Written as ETBX-011How we know
- QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedPhase 1/2ImmunityBio, Inc.NCT03387111Written as ETBX-011How we know
- QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedPhase 1/2ImmunityBio, Inc.NCT03136406Written as ETBX-011How we know
- QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedPhase 1/2ImmunityBio, Inc.NCT03387098Written as ETBX-011How we know
- QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineWithdrawnPhase 1/2ImmunityBio, Inc.NCT03563170Written as ETBX-011How we know
- Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced CancerCompletedPhase 1National Cancer Institute (NCI)NCT03384316Written as ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccineHow we know
Given beside what is tested · 1 — ETBX-011 is usual care or a partner of the new treatment
Codes
What other systems call ETBX-011 · ClinicalTrials.gg INT017816
- UNII (FDA) RP9RQ0SOM8ETBX-011One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | RP9RQ0SOM8 | ETBX-011 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.